ClinicalTrials.gg
Active, not recruitingNCT04812925ADVANCE SC+Updated Oct 19, 2026

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

A Phase 3 interventional study of efgartigimod PH20 SC in Primary Immune Thrombocytopenia, sponsored by argenx. Active, not recruiting at 83 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
173
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 82 open to participants now, 92 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Enrollment
25th of 167
173 · median 62
Started
2021
with 15 others
Phase 3
39 of 185
7 open now
Primary completion
2027-10
later than 71 of 91 live
Registered
71st of 185
by date
Lead sponsor
3 of 185
argenx

Among the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 25th largest by enrollment of the 167 interventional ones that give a count, is one of 16 that started in 2021, is one of 39 in phase 3, reaches primary completion later than 71 of the 91 other live ones, and was the 71st registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

82 of the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

The main aim of the study is to evaluate the safety and efficacy of efgartigimod PH20 SC (subcutaneous) in adult patients with primary immune thrombocytopenia (ITP). Participants who completed the 24-week trial period of the ARGX- 113-2004 trial are given the opportunity to enter into this open-label extension trial and receive efgartigimod PH20 SC.

Participants will be offered the opportunity to continue in this trial if they have completed the first 52-week treatment period unless efgartigimod becomes commercially available for patients with primary ITP or becomes available through another program for patients with primary ITP, whichever comes first. A maximum of three additional 52-week treatment periods will be offered to the participant to continue this trial.

The total trial duration per participant is up to 4 years (52-week treatment period, extendable with three additional 52-week treatment periods) + 8 weeks follow-up period.

03

Conditions studied

  • Primary Immune Thrombocytopenia
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand the requirements of the trial and provide written (including consent for the use and disclosure of research-related health information), willing and able to comply with the trial protocol procedures (including attending the required trial visits).
  • Participants enrolled in the ARGX-113-2004 trial who completed the 24-week trial period.
  • Agree to use consistent with local regulations.
  • In addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period, the participant has completed a 52-week treatment period.

Exclusion criteria

Exclusion criteria:

  • Introduction or continuation of nonpermitted medications during the ARGX-113-2004 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins, or live/).
  • Use of any other drug or participation in any other investigational trial.
  • Known reaction to efgartigimod PH20 SC or any of its .
  • Pregnant or lactating females and those who intend to become pregnant during the trial or within 90 days after last dose of efgartigimod PH20 SC.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    efgartigimod PH20 SC

    Patients receiving efgartigimod PH20 SC treatment

    Biological: efgartigimod PH20 SC

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of AEs, AESIs, SAEs

    AE : adverse event ; SAE : Serious adverse event ; AESI : adverse event of special interest.

    Time frame: Up to 216 weeks

  2. Vital sign measurement: blood pressure in the overall population

    Time frame: Up to 216 weeks

  3. ECG: PR, QT and QRS interval in the overall population

    Time frame: Up to 216 weeks

  4. Laboratory safety evaluations: CRP analysis in the overall population

    Time frame: Up to 216 weeks

Secondary outcomes

  1. Extent of disease control defined as the percentage of weeks in the trial with platelet counts of ≥50×10E9/L

    Time frame: Up to 52 weeks

  2. Proportion of participants with overall platelet count response defined as achieving a platelet count of ≥50×10E9/L on at least 4 occasions at any time during the 52-week treatment period

    Time frame: Up to 52 weeks

  3. Mean change from baseline in platelet count at each visit

    Time frame: Up to 52 weeks

  4. For participants rolling over from the ARGX-113-2004 trial with a platelet count of <30×10E9/L: time to response defined as the time to achieve 2 consecutive platelet counts of ≥50×10E9/L

    Time frame: Up to 52 weeks

  5. The percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline

    Time frame: Up to 52 weeks

  6. In patients with a baseline platelet count of <15×10E9/L in the current trial (ARGX-113-2005), the percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline

    Time frame: Up to 52 weeks

  7. In participants with the first exposure to efgartigimod PH20 SC, the proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of ≥50×10E9/L for at least 4 of the 6 visits between week 19 and week 24

    Time frame: 5 weeks (from week 19 to week 24)

  8. In participants with the first exposure to efgartigimod PH20 SC, the proportion of patients achieving platelet counts of ≥50×10E9/L for at least 6 of the 8 visits between week 17 and week 24

    Time frame: 7 weeks (from week 17 to week 24)

  9. Proportion of participants for whom dose and/or frequency of concurrent ITP therapies have been reduced compared to baseline

    Time frame: Up to 52 weeks

  10. Rate of receipt of rescue therapy (rescue per participant per month)

    Time frame: Up to 52 weeks

  11. Incidence of the WHO-classified bleeding events

    WHO : World Health Organization

    Time frame: Up to 52 weeks

  12. Serum efgartigimod concentration observed predose (Ctrough)

    Time frame: Up to 52 weeks

  13. Change from baseline in FACIT-fatigue at planned visits

    The Functional Assessment of Chronic Illness Therapy Fatigue (FACIT- fatigue) scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured by recording item responses on a 4-point Likert scale ranging from 0 "not at all" to 4 "very much."

    Time frame: Up to 52 weeks

  14. Change from baseline in FACT-Th6 at planned visits

    The Functional Assessment of Cancer Therapy questionnaire-Th6 (FACT-Th6) uses the Likert scale, with participants rating their degree of concern in the past 7 days. The 6 selected items pertain to ability to do usual activities, worry about problems with bleeding or bruising, worry about the possibility of serious bleeding, avoidance of physical or social activity because of concern with bleeding or bruising and frustration due to the inability to carry out usual activities.

    Time frame: Up to 52 weeks

  15. Change from baseline in SF-36 at planned visits

    The SF-36 is a 36-item scale constructed to survey health-related QoL on 8 domains: limitations in physical activities due to health problems; limitations in social activities due to physical or emotional problems; limitations in usual role activities due to physical health problems; bodily pain; general mental health (psychological distress and well being); limitations in usual role activities due to emotional problems; vitality (energy and fatigue); and general health perceptions.

    Time frame: Up to 52 weeks

  16. Change from baseline in ITP-PAQ at planned visits

    The ITP-Patient Assessment Questionnaire (ITP-PAQ) is a 44-item questionnaire to assess the health-related QoL in adults with ITP. It includes scales for physical health (symptoms, fatigue/sleep, bother, and activity), emotional health (psychological and fear), overall QoL, social activity, women's reproductive health, and work.

    Time frame: Up to 52 weeks

  17. Pharmacodynamics markers: total IgG

    Time frame: Up to 52 weeks

  18. Percentage of participants who performed self-administration at home over time

    Time frame: Up to 52 weeks

  19. Percentage of caregivers who administered the injection to the patient at home over time

    Time frame: Up to 52 weeks

  20. Number of training visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC

    Time frame: Up to 52 weeks

  21. Percentage of self- or caregiver-supported administrations at home

    Time frame: Up to 52 weeks

  22. Incidence of antibodies to efgartigimod

    Time frame: Up to 216 weeks

  23. Titers of antibodies to efgartigimod

    Time frame: Up to 216 weeks

  24. Presence of NAb against efgartigimod

    NAb : Neutralizing antibodies

    Time frame: Up to 216 weeks

07

Study locations

83 sites
  • Investigator Site 0010116
    Bentonville, Arkansas 72758, United States
  • Investigator site 0010045
    Washington D.C., District of Columbia 20007, United States
  • Investigator Site 0010062
    Fort Wayne, Indiana 46804, United States
  • Investigator site US0010042
    Iowa City, Iowa 52242, United States
  • Investigator Site 0010095
    Oklahoma City, Oklahoma 73142, United States
  • Investigator Site 0540001
    Buenos Aires, Argentina
  • Investigator site 540004
    Buenos Aires, Argentina
  • Investigator Site 0610012
    Garran, Australia
  • Investigator Site 0610003
    West Perth, Australia
  • Investigator site 610005
    Westmead, Australia
  • Investigator Site 3590017
    Plovdiv, Bulgaria
  • Investigator site 0560003
    Reñaca, Chile
  • Investigator site 560002
    Santiago, Chile
  • Investigator site 0560004
    Temuco, Chile
  • Investigator site 860013
    Beijing, China
  • Investigator Site 0860008
    Bengbu, China
  • Investigator site 860055
    Huizhou, China
  • Investigator Site 0860015
    Shenzhen, China
  • Investigator Site 0860001
    Tianjin, China
  • Investigator Site 0860010
    Wuhan, China
  • Investigator Site 0860002
    Wuxi, China
  • Investigator Site 0860011
    Zhengzhou, China
  • Investigator site 860058
    Zhenjiang, China
  • Investigator Site 9950007
    Tbilisi, Georgia
  • Investigator site 9950009
    Tbilisi, Georgia
  • Investigator site 9950011
    Tbilisi, Georgia
  • Investigator site 300008
    Athens, Greece
  • Investigator Site 0300009
    Thessaloniki, Greece
  • Investigator site 3530003
    Dublin, Ireland
  • Investigator site 390043
    Ferrara, Italy
  • Investigator Site 0390032
    Milan, Italy
  • Investigator Site 0390044
    Naples, Italy
  • Investigator site 390041
    Naples, Italy
  • Investigator site JP0810015
    Hirakata, 5731191, Japan
  • Investigator Site 0810017
    Iruma, Japan
  • Investigator Site 0810053
    Kanagawa, Japan
  • Investigator Site 0810051
    Kitakyushu, Japan
  • Investigator site 0810016
    Shibukawa, 377-0280, Japan
  • Investigator site 810023
    Shimotsuke, Japan
  • Investigator Site 0810038
    Tama, Japan
  • Investigator site 9620001
    Irbid, Jordan
  • Investigator site 520002
    Aguascalientes, Mexico
  • Investigator site 640005
    Christchurch, New Zealand
  • Investigator site 0470003
    Sarpsborg, 1714, Norway
  • Investigator site PL0480013
    Katowice, 40-519, Poland
  • Investigator Site 0480026
    Nowy Sącz, Poland
  • Investigator Site 0480037
    Skorzewo, Poland
  • Investigator Site 3510007
    Lisbon, Portugal
  • Investigator site 3510004
    Porto, Portugal
  • Investigator site 3510001
    Vila Nova de Gaia, Portugal
  • Investigator Site 0400005
    Bucharest, Romania
  • Investigator site 400012
    Bucharest, Romania
  • Investigator Site 0400007
    Craiova, Romania
  • Investigator site 0070040
    Kirov, Russia
  • Investigator Site 0070026
    Moscow, Russia
  • Investigator Site 0070038
    Nizhny Novgorod, Russia
  • Investigator Site 0070037
    Novosibirsk, Russia
  • Investigator site 270003
    Johannesburg, South Africa
  • Investigator site 270004
    Observatory, South Africa
  • Investigator site 270001
    Pretoria, South Africa
  • Investigator site 270002
    Randburg, South Africa
  • Investigator site 820004
    Seoul, South Korea
  • Investigator site KO0820007
    Seoul, South Korea
  • Investigator Site 0660002
    Bangkok, Thailand
  • Investigator Site 0660003
    Bangkok, Thailand
  • Investigator site 660005
    Bangkok, Thailand
  • Investigator Site 0660001
    Bangkok Noi, Thailand
  • Investigator site 0660004
    Chiang Mai, 50200, Thailand
  • Investigator site TH0660009
    Khon Kaen, Thailand
  • Investigator site 2610001
    Sousse, Tunisia
  • Investigator site 2160002
    Tunis, Tunisia
  • Investigator Site 0900007
    Adapazarı, Turkey (Türkiye)
  • Investigator Site 0900003
    Ankara, Turkey (Türkiye)
  • Investigator Site 0900008
    Ankara, Turkey (Türkiye)
  • Investigator Site 0900015
    Ankara, Turkey (Türkiye)
  • Investigator site 900004
    Izmir, Turkey (Türkiye)
  • Investigator Site 0900014
    Kocaeli, Turkey (Türkiye)
  • Investigator site 900010
    Mersin, Turkey (Türkiye)
  • Investigator site 0900017
    Tekirdağ, 59100, Turkey (Türkiye)
  • Investigator site 900019
    Trabzon, Turkey (Türkiye)
  • Investigator site 440005
    Coventry, United Kingdom
  • Investigator site UK044041
    London, United Kingdom
  • Investigator site UK0440014
    Penzance, TR18 2PF, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Oct 2027, 71 months after the start.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's planned 71 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2021
First posted
Mar 24, 2021
StartActual
Nov 17, 2021
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Oct 2027
Oct 19, 2026
Study completion
Oct 1, 2026→Oct 2027
Oct 19, 2026
Eligibility
2 inclusion criteria edited, 4 removed
What changed in the criteria
Inclusion criteria
  • RemovedNote: If a participant has had an SAE during the ARGX-113-2004 trial, their eligibility should be evaluated by the investigator and the sponsor's trial physician. The decision of enrolling the participant will be evaluated case by case.
  • Edited3a. Agree to use contraceptives consistent with local regulations and the following:.
  • RemovedFemale participants of childbearing potential must have a negative urine pregnancy test at baseline before receiving IMP.
  • EditedIn addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period (only applicable in case efgartigimod is not yet commercially available for patients with primary ITP or available through another patient program for patients with primary ITP), the following criteria apply:participant has completed a 52-week treatment period.
  • Removed4. Ability to understand the requirements of the additional 52-week treatment period of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).
  • Removed5. Participant has completed a 52-week treatment period.
Oct 19, 2026
Primary outcomes
1 edited, 3 time frame changed
What changed in the outcomes
  • ChangedBefore Incidence, frequency, and severity of adverse events (AEs), AEs of special interest (AESIs), and serious AEs (SAEs)Now Incidence of AEs, AESIs, SAEsTime frame: 216 weeks → Up to 216 weeks
  • Time frameVital sign measurement: blood pressure in the overall population216 weeks → Up to 216 weeks
  • Time frameECG: PR, QT and QRS interval in the overall population216 weeks → Up to 216 weeks
  • Time frameLaboratory safety evaluations: CRP analysis in the overall population216 weeks → Up to 216 weeks
Oct 19, 2026
Secondary outcomes
13 edited, 10 time frame changed, 1 added, 4 removed
What changed in the outcomes
  • EditedProportion of patientsparticipants with overall platelet count response defined as achieving a platelet count of ≥50×10E9/L on at least 4 occasions at any time during the 52-week treatment periodTime frame: 52 weeks → Up to 52 weeks
  • EditedFor patientsparticipants rolling over from the ARGX-113-2004 trial with a platelet count of <30×10E9/L: time to response defined as the time to achieve 2 consecutive platelet counts of ≥50×10E9/LTime frame: 52 weeks → Up to 52 weeks
  • EditedIn patientsparticipants with the first exposure to efgartigimod PH20 SC, the proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of ≥50×10E9/L for at least 4 of the 6 visits between week 19 and week 24Time frame: 5 weeks (week 19-24) → 5 weeks (from week 19 to week 24)
  • EditedIn patientsparticipants with the first exposure to efgartigimod PH20 SC, the proportion of patients achieving platelet counts of ≥50×10E9/L for at least 6 of the 8 visits between week 17 and week 24Time frame: 7 weeks (week 17-24) → 7 weeks (from week 17 to week 24)
  • EditedProportion of patientsparticipants for whom dose and/or frequency of concurrent ITP therapies have been reduced compared to baselineTime frame: 52 weeks → Up to 52 weeks
  • EditedRate of receipt of rescue therapy (rescue per patientparticipant per month)Time frame: 52 weeks → Up to 52 weeks
  • EditedIncidence of the World Health Organization (WHO)-classified bleeding eventsTime frame: 52 weeks → Up to 52 weeks
  • EditedChange from baseline in PRO (Functional Assessment of Chronic Illness Therapy Fatigue Scale [FACIT-fatigue]) at planned visitsTime frame: 52 weeks → Up to 52 weeks
  • EditedChange from baseline in PRO (Functional Assessment of Cancer Therapy questionnaire-Th6 [FACT-Th6]) at planned visitsTime frame: 52 weeks → Up to 52 weeks
  • EditedChange from baseline in PRO (QoL (Short Form-36 [SF-36]) at planned visitsTime frame: 52 weeks → Up to 52 weeks
  • EditedNumberPercentage of patientsparticipants who performed self-administration at home over timeTime frame: 52 weeks → Up to 52 weeks
  • EditedIncidence and prevalence of antibodies to efgartigimodTime frame: 216 weeks → Up to 216 weeks
  • EditedPresence of neutralizing antibodies (NAb) against efgartigimodTime frame: 216 weeks → Up to 216 weeks
  • AddedChange from baseline in ITP-PAQ at planned visitsTime frame: Up to 52 weeks
  • RemovedSeverity of the World Health Organization (WHO)-classified bleeding eventsTime frame: 52 weeks
  • RemovedPercentage of patients who performed self-administration at home over timeTime frame: 52 weeks
  • RemovedNumber of caregivers who administered the injection to the patient at home over timeTime frame: 52 weeks
  • RemovedNumber of self- or caregiver-supported administrations at homeTime frame: 52 weeks
  • Time frameExtent of disease control defined as the percentage of weeks in the trial with platelet counts of ≥50×10E9/L52 weeks → Up to 52 weeks
  • Time frameMean change from baseline in platelet count at each visit52 weeks → Up to 52 weeks
  • Time frameThe percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline52 weeks → Up to 52 weeks
  • Time frameIn patients with a baseline platelet count of <15×10E9/L in the current trial (ARGX-113-2005), the percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline52 weeks → Up to 52 weeks
  • Time frameSerum efgartigimod concentration observed predose (Ctrough)52 weeks → Up to 52 weeks
  • Time framePharmacodynamics markers: total IgG52 weeks → Up to 52 weeks
  • Time framePercentage of caregivers who administered the injection to the patient at home over time52 weeks → Up to 52 weeks
  • Time frameNumber of training visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC52 weeks → Up to 52 weeks
  • Time framePercentage of self- or caregiver-supported administrations at home52 weeks → Up to 52 weeks
  • Time frameTiters of antibodies to efgartigimod216 weeks → Up to 216 weeks
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Oct 1, 2026→Oct 2027
    Study completion Oct 1, 2026→Oct 2027
    Eligibility 2 inclusion criteria edited, 4 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedNote: If a participant has had an SAE during the ARGX-113-2004 trial, their eligibility should be evaluated by the investigator and the sponsor's trial physician. The decision of enrolling the participant will be evaluated case by case.
    • Edited3a. Agree to use contraceptives consistent with local regulations and the following:.
    • RemovedFemale participants of childbearing potential must have a negative urine pregnancy test at baseline before receiving IMP.
    • EditedIn addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period (only applicable in case efgartigimod is not yet commercially available for patients with primary ITP or available through another patient program for patients with primary ITP), the following criteria apply:participant has completed a 52-week treatment period.
    • Removed4. Ability to understand the requirements of the additional 52-week treatment period of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).
    • Removed5. Participant has completed a 52-week treatment period.
    Primary outcomes 1 edited, 3 time frame changed
    What changed in the outcomes
    • ChangedBefore Incidence, frequency, and severity of adverse events (AEs), AEs of special interest (AESIs), and serious AEs (SAEs)Now Incidence of AEs, AESIs, SAEsTime frame: 216 weeks → Up to 216 weeks
    • Time frameVital sign measurement: blood pressure in the overall population216 weeks → Up to 216 weeks
    • Time frameECG: PR, QT and QRS interval in the overall population216 weeks → Up to 216 weeks
    • Time frameLaboratory safety evaluations: CRP analysis in the overall population216 weeks → Up to 216 weeks
    Secondary outcomes 13 edited, 10 time frame changed, 1 added, 4 removed
    What changed in the outcomes
    • EditedProportion of patientsparticipants with overall platelet count response defined as achieving a platelet count of ≥50×10E9/L on at least 4 occasions at any time during the 52-week treatment periodTime frame: 52 weeks → Up to 52 weeks
    • EditedFor patientsparticipants rolling over from the ARGX-113-2004 trial with a platelet count of <30×10E9/L: time to response defined as the time to achieve 2 consecutive platelet counts of ≥50×10E9/LTime frame: 52 weeks → Up to 52 weeks
    • EditedIn patientsparticipants with the first exposure to efgartigimod PH20 SC, the proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of ≥50×10E9/L for at least 4 of the 6 visits between week 19 and week 24Time frame: 5 weeks (week 19-24) → 5 weeks (from week 19 to week 24)
    • EditedIn patientsparticipants with the first exposure to efgartigimod PH20 SC, the proportion of patients achieving platelet counts of ≥50×10E9/L for at least 6 of the 8 visits between week 17 and week 24Time frame: 7 weeks (week 17-24) → 7 weeks (from week 17 to week 24)
    • EditedProportion of patientsparticipants for whom dose and/or frequency of concurrent ITP therapies have been reduced compared to baselineTime frame: 52 weeks → Up to 52 weeks
    • EditedRate of receipt of rescue therapy (rescue per patientparticipant per month)Time frame: 52 weeks → Up to 52 weeks
    • EditedIncidence of the World Health Organization (WHO)-classified bleeding eventsTime frame: 52 weeks → Up to 52 weeks
    • EditedChange from baseline in PRO (Functional Assessment of Chronic Illness Therapy Fatigue Scale [FACIT-fatigue]) at planned visitsTime frame: 52 weeks → Up to 52 weeks
    • EditedChange from baseline in PRO (Functional Assessment of Cancer Therapy questionnaire-Th6 [FACT-Th6]) at planned visitsTime frame: 52 weeks → Up to 52 weeks
    • EditedChange from baseline in PRO (QoL (Short Form-36 [SF-36]) at planned visitsTime frame: 52 weeks → Up to 52 weeks
    • EditedNumberPercentage of patientsparticipants who performed self-administration at home over timeTime frame: 52 weeks → Up to 52 weeks
    • EditedIncidence and prevalence of antibodies to efgartigimodTime frame: 216 weeks → Up to 216 weeks
    • EditedPresence of neutralizing antibodies (NAb) against efgartigimodTime frame: 216 weeks → Up to 216 weeks
    • AddedChange from baseline in ITP-PAQ at planned visitsTime frame: Up to 52 weeks
    • RemovedSeverity of the World Health Organization (WHO)-classified bleeding eventsTime frame: 52 weeks
    • RemovedPercentage of patients who performed self-administration at home over timeTime frame: 52 weeks
    • RemovedNumber of caregivers who administered the injection to the patient at home over timeTime frame: 52 weeks
    • RemovedNumber of self- or caregiver-supported administrations at homeTime frame: 52 weeks
    • Time frameExtent of disease control defined as the percentage of weeks in the trial with platelet counts of ≥50×10E9/L52 weeks → Up to 52 weeks
    • Time frameMean change from baseline in platelet count at each visit52 weeks → Up to 52 weeks
    • Time frameThe percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline52 weeks → Up to 52 weeks
    • Time frameIn patients with a baseline platelet count of <15×10E9/L in the current trial (ARGX-113-2005), the percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline52 weeks → Up to 52 weeks
    • Time frameSerum efgartigimod concentration observed predose (Ctrough)52 weeks → Up to 52 weeks
    • Time framePharmacodynamics markers: total IgG52 weeks → Up to 52 weeks
    • Time framePercentage of caregivers who administered the injection to the patient at home over time52 weeks → Up to 52 weeks
    • Time frameNumber of training visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC52 weeks → Up to 52 weeks
    • Time framePercentage of self- or caregiver-supported administrations at home52 weeks → Up to 52 weeks
    • Time frameTiters of antibodies to efgartigimod216 weeks → Up to 216 weeks
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04812925
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Mar 24, 2021
Start date
Nov 17, 2021
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion